**Wednesday, October 20, 2021**

**10:00** Welcome & Introductions  
Dr. Grace Lee (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

**10:30** Agency Updates

**10:45** Pneumococcal Vaccines  
Introduction  
Considerations for age-based and risk-based use of PCV15/PCV20 among adults and proposed policy options  
Discussion  
Dr. Katherine Poehling (ACIP, WG Chair)  
Dr. Miwako Kobayashi (CDC/NCIRD)

**1:15** Zoster Vaccines  
Introduction  
Work group interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options  
Discussion  
Dr. Camille Kotton (ACIP, WG Chair)  
Dr. Tara Anderson (CDC/NCIRD)  
Dr. Tara Anderson (CDC/NCIRD)

**2:15** Break

**2:30** Influenza Vaccines  
Introduction  
Phase II safety and immunogenicity study of the coadministration of Fluzone® High-Dose Quadrivalent Influenza Vaccine and a third dose of Change in Age Indication for Flucelvax Quadrivalent  
Discussion  
Dr. Keipp Talbot (ACIP, WG Chair)  
Dr. Ruvim Izikson (Sanofi Pasteur)  
Dr. Lisa Grohskopf (CDC/NCIRD)

**3:30** Break

**3:45** Public Comment

**4:20** Break

**4:20** Votes  
Pneumococcal Vote  
Zoster Vote  
Dr. Miwako Kobayashi (CDC/NCIRD)  
Dr. Tara Anderson (CDC/NCIRD)

**5:00** Adjourn

**Thursday, October 21, 2021**

**10:00** Welcome & Introductions  
Dr. Grace Lee (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

**10:15** Coronavirus Disease 2019 (COVID-19) Vaccines  
Introduction  
Moderna- Booster dose data  
Janssen- Booster dose data  
National Institututes of Health, Mix and Match booster study  
Dr. Matthew Daley (ACIP, WG Chair)  
Dr. Jacqueline Miller (Moderna)  
Dr. Penny Heaton & Dr. Macaya Douoguih (Janssen)  
Dr. Robert Atmar (Baylor College of Medicine)

**11:45** Break

**12:00** Public comment

**12:40** v-safe and VAERS - third dose and simultaneous vaccination  
COVID-19 Vaccine Safety Updates  
Myocarditis- VAERS  
Myocarditis- VSD  
VaST Assessment  
Dr. Anne Hause (CDC/NCEZID)  
Dr. Tom Shimabukuro (CDC/NCEZID)  
Dr. John Su (CDC/NCEZID)  
Dr. Nicky Klein (KPCN)  
Dr. Keipp Talbot (VaST Chair)

**2:05** Break

**2:20** COVID-19 vaccine effectiveness, primary series  
Evidence to Recommendations  
Clinical considerations  
Policy Questions  
Dr. Jefferson Jones (CDC/NCIRD)  
Dr. Kathleen Dooling (CDC/NCIRD)  
Dr. Sujan Reddy (CDC/NCEZID)  
Dr. Kathleen Dooling (CDC/NCIRD)

**4:20** Vote

**5:00** Adjourn
**Acronyms**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus disease 2019</td>
</tr>
<tr>
<td>E2R</td>
<td>Evidence to Recommendations Framework</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development and Evaluation</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>NCHHSTP</td>
<td>National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]</td>
</tr>
<tr>
<td>NCIRD</td>
<td>National Center for Immunization &amp; Respiratory Diseases [of CDC/OID]</td>
</tr>
<tr>
<td>NCEZID</td>
<td>National Center for Emerging and Zoonotic Diseases [of CDC/OID]</td>
</tr>
<tr>
<td>NIAID</td>
<td>National Institute of Allergy and Infectious Diseases</td>
</tr>
<tr>
<td>OIDP</td>
<td>Office of Infectious Disease and HIV/AIDS Policy</td>
</tr>
<tr>
<td>RZV</td>
<td>Recombinant Zoster Vaccine</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Severe Acute Respiratory Syndrome Coronavirus 2</td>
</tr>
<tr>
<td>WG</td>
<td>Work Group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>VE</td>
<td>Vaccine Effectiveness</td>
</tr>
</tbody>
</table>